Quality markers for nootropic peptides — intranasal vs injectable purity standards

Cognitive peptide quality verification has its own specific considerations. The intranasal administration route changes some of the quality requirements (lower endotoxin tolerance for nasal mucosa than for subcutaneous tissue, but no requirement for sterile filtration in some research contexts), the Cerebrolysin porcine-brain origin creates source-verification challenges that single-peptide compounds do not have, and the Dihexa research base is thin enough that vendor-quality verification is harder than for established compounds. This thread covers what to look for on a COA across the different compounds in this category.

The basics still apply.
The general COA-reading skills covered in the COA & Lab Results category apply here. HPLC purity, mass spectrometry confirmation of identity, named accredited third-party lab, specific batch number matching the vial. If those basics are not present, do not buy regardless of category. This thread covers the additional considerations specific to cognitive peptides.

Acceptable purity thresholds.
For research-grade cognitive peptides, HPLC purity above 97% is the minimum acceptable threshold for the single-peptide compounds (Semax, Selank, Dihexa). Above 98% is good. Above 99% is excellent.

Cerebrolysin is fundamentally different because it is a mixture rather than a single compound — "purity" in the conventional HPLC sense does not apply the same way. Cerebrolysin quality verification is covered separately below.

Mass spectrometry expectations.

Semax: theoretical molecular weight 813.93 Da (heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro).

Selank: theoretical molecular weight 751.86 Da (heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro).

Dihexa: theoretical molecular weight 504.28 Da (the angiotensin-IV-derived modified dipeptide structure with hexanoyl modifications).

Cerebrolysin: not characterizable as a single mass because it is a mixture. Quality verification is by other methods.

The mass spec value on the COA must match the theoretical weight for the labeled compound. This is the single most important check for ruling out substitution where one cognitive peptide is being labeled as another or where an unrelated peptide is being labeled as a cognitive peptide.

Intranasal-specific quality considerations.

Compounds intended for intranasal administration have some quality requirements that differ from injectables.

Endotoxin tolerance is lower for nasal mucosa than for subcutaneous injection. The nasal mucosa has different sensitivity to bacterial endotoxins than subcutaneous tissue. Endotoxin testing should appear on the COA with values below the standard threshold (less than 5 EU/mg).

pH and tonicity matter for nasal absorption. Intranasal formulations should be near physiological pH (around 6.0-7.0) and isotonic. Vendors providing reconstitution guidance for intranasal use should specify the appropriate buffer or saline formulation.

Carrier and preservative considerations for intranasal sprays. If the product is sold as a pre-formulated nasal spray (rather than as lyophilized powder for the customer to reconstitute), the carrier formulation, preservative system, and stability of the formulation become quality issues. Most research-grade cognitive peptides are sold as lyophilized powder for customer reconstitution; pre-formulated sprays add quality variables that the customer cannot easily verify.

Cerebrolysin-specific quality considerations.

Cerebrolysin is the most quality-challenging compound in this category to verify because it is a porcine-brain-derived peptide complex rather than a single synthetic peptide. The quality considerations are different from anything else in the cognitive category.

Source verification is critical. Authentic Cerebrolysin is manufactured by a small number of pharmaceutical companies (most prominently EVER Pharma, the original developer) under controlled conditions with documented chain of custody from porcine brain source through processing to final product. Counterfeit Cerebrolysin is a real problem in the research community — products sold as "Cerebrolysin" that are not from a verified source may contain anything from a lower-quality peptide complex to entirely different content.

The porcine origin creates specific verification challenges. The peptide complex composition cannot be characterized by simple mass spec the way a single peptide can. Authentic Cerebrolysin has a documented composition profile that established analytical methods can verify, but vendors selling "Cerebrolysin" without manufacturer chain-of-custody documentation cannot confirm authenticity through ordinary peptide quality testing.

The clinically-used product is sold as ampoules, not vials. Authentic pharmaceutical Cerebrolysin is supplied as sealed glass ampoules with specific labeling, lot numbers, and pharmacy distribution. Vials of "Cerebrolysin" sold through research peptide vendors are by definition not the pharmaceutical product and quality verification is much harder.

The practical implication: if you cannot trace the Cerebrolysin product back to a verified manufacturer through documented chain of custody, the quality is fundamentally unverifiable. The research peptide vendor channel cannot reliably provide quality-verified Cerebrolysin and buyers should treat any "Cerebrolysin" from that channel as unverifiable regardless of the vendor's claims.

Dihexa-specific quality considerations.

The Dihexa research base is thin enough that quality benchmarks are less established than for compounds with longer research histories. The basic peptide quality markers apply (HPLC purity, mass spec confirmation of the 504.28 Da molecular weight, named third-party lab) but the lack of established research-grade vendor benchmarks means the buyer is taking on more quality risk than for compounds where dozens of vendors have been compared over years.

The marketing claims around Dihexa often outrun the data. A vendor making strong cognitive-effect claims for Dihexa is signaling marketing-driven framing rather than evidence-driven framing — and that often correlates with looser documentation standards.

What a strong cognitive peptide COA looks like in practice.

For Semax or Selank: HPLC purity above 97% with chromatogram showing one dominant peak. Mass spectrometry confirming the theoretical molecular weight. Endotoxin testing below threshold (especially important for intranasal use). Acetate content or net peptide content reported. Named accredited third-party lab.

For Cerebrolysin: documented manufacturer chain of custody traceable to a verified pharmaceutical source. Authentic packaging (sealed ampoules with manufacturer labeling). If those are not present, the quality is unverifiable regardless of any peptide testing the vendor provides.

For Dihexa: HPLC purity above 97%, mass spec confirming 504.28 Da, named third-party lab. Conservative interpretation of any marketing claims given the thin research base.

If you are evaluating a vendor for any cognitive peptide, request the COA before ordering and verify the specific quality markers that apply. Cerebrolysin specifically deserves extra skepticism — the pharmaceutical product has a well-defined chain of custody, and "Cerebrolysin" sold through research peptide vendors should be approached with substantial caution. Post questions or specific COAs in the Quality and COA discussion threads if you want a second pair of eyes.